Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of CancerGlobeNewsWire • Wednesday
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 11/07/24
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 11/04/24
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 10/07/24
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo MinegishiGlobeNewsWire • 09/23/24
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline ProgressGlobeNewsWire • 08/13/24
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of DirectorsGlobeNewsWire • 07/31/24
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor ConferenceGlobeNewsWire • 06/05/24
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/24
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/24/24
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual MeetingGlobeNewsWire • 04/09/24
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/26/24
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/05/24
Recent Spin Mural Oncology At An Attractive Discount To Cash And Portfolio ValueSeeking Alpha • 03/04/24